Pfizer Inc. $PFE Shares Sold by Strategic Blueprint LLC

Strategic Blueprint LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.7% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 38,830 shares of the biopharmaceutical company’s stock after selling 6,169 shares during the quarter. Strategic Blueprint LLC’s holdings in Pfizer were worth $941,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the second quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Morgan Stanley dropped their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Trading Up 0.5%

Pfizer stock opened at $24.79 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.17. The stock’s 50 day simple moving average is $24.87 and its two-hundred day simple moving average is $24.17. The firm has a market cap of $140.92 billion, a PE ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.